Am J Transplant, Volume 17, Suppl 3 Archives - Page 2 of 181 - ATC Abstracts

2017 American Transplant Congress
Transplantation of Organs from Donors with Hepatitis C: The Potential to Substantially Increase Transplant Activity.
P. Trotter,^1,2 M. Robb,² I. Ushiro-Lumb,² J. Powell,³ C. Watson,¹ J. Bradley,¹ J. Neuberger.^2,4
¹Department of Surgery, University of Cambridge, Cambridge, United Kingdom; ²Organ Donation and Transplantation, National Health Service Blood and Transplant, Bristol, United Kingdom; ³Hepatic-Pancreatico-Biliary Surgical Services and Edinburgh Transplant Unit, Royal Infirmary Edinburgh, Edinburgh, United Kingdom; ⁴The Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom
Introduction. Organs from hepatitis C virus positive (HCV+ve) donors are commonly declined for transplantation because of the risk of disease transmission, but new direct acting…
2017 American Transplant Congress
Assessment of the Association Between Measures of Metabolic Function and Pancreas Graft Survival.
S. Mittal,¹ R. Franklin,² J. Levy,² S. Gough,² E. Sharples,¹ P. Friend.¹
¹Department of Renal Transplantation, Oxford Transplant Centre, Oxford, United Kingdom; ²Department of Diabetology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, United Kingdom
Introduction: The lack of a validated measure of graft function after pancreas implantation has hindered our ability to monitor recipients post-transplant and identify declines in…
2017 American Transplant Congress
TIM-3 – CEACAM1 Checkpoint Regulation of T-Cell Activation and Hepatocellular Function in Liver Transplantation.
K. Nakamura,¹ S. Kageyama,¹ M. Kujawski,³ R. Sosa,² E. Reed,² A. Zarrinpar,¹ R. Busuttil,¹ J. Kupiec-Weglinski.¹
¹Dept. Surgery, UCLA, Los Angeles, CA; ²Dept. Pathology, UCLA, Los Angeles, CA; ³Dept. Molecular Immunology, City of Hope, Duarte, CA
Background/Aim: We have documented crucial role of TIM-3 dependent T cell dysfunction in mouse orthotopic liver transplantation (OLT). CEACAM1 (CD66a; CM1; Carcinoembryonic Antigen-Related Cell Adhesion…
2017 American Transplant Congress
Successful Induction of Tolerance of Fully Allogeneic Lung Graft with Adenosine A_2A Receptor (A2AR) Agonist in MHC-Defined CLAWN Miniature Swine.
H. Sahara, M. Sekijima, T. Murokawa, Y. Ariyoshi, T. Iwanaga, Y. Ichinari, A. Shimizu, K. Yamada.
Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan
Introduction: A2AR agonist is known to potently attenuate lung ischemia-reperfusion injury. However, the long-term effects of A2AR agonist on lung allograft survival remain unclear especially…
2017 American Transplant Congress
Antibodies to Angiotensin Type II Receptor I Are Associated with Primary Graft Dysfunction After Orthotopic Heart Transplant in Patients with Ventricular Assist Device as Bridge to Transplant.
M. Hickey,¹ E. DePasquale,² S. Shah,³ D. Vucicevic,² J. Zhang,¹ N. Valenzuela,¹ M. Deng,² E. Reed.¹
¹UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA; ²UCLA Division of Cardiology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA; ³UCLA David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Primary graft dysfunction (PGD) following orthotopic heart transplant (OHT) is one of the leading causes of posttransplant mortality. We hypothesized that antibody to angiotensin type…
2017 American Transplant Congress
Dementia and Alzheimer's Disease Among Older Kidney Transplant Recipients.
M. McAdams DeMarco, S. Bae, N. Chu, A. Gross, C. Brown IV, E. Oh, P. Rosenberg, K. Neufeld, R. Varadhan, M. Albert, J. Walston, D. Segev.
Johns Hopkins, Baltimore, MD
Background: Kidney transplantation (KT) is a growing treatment option for older ESRD patients. Older recipients may develop post-KT dementia and Alzheimer's disease (AD) associated with…
2017 American Transplant Congress
Post-Donation GFR Changes in Living Kidney Donors.
E. Poggio,¹ S. Arrigain,² J. Augustine,¹ S. Flechner,³ J. Schold.²
¹Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH; ²Qualitative Health Sciences, Cleveland Clinic, Cleveland, OH; ³Urology, Cleveland Clinic, Cleveland, OH
Living kidney donor transplantation is the preferred treatment for ESRD because it confers excellent outcomes for recipients and poses reasonable risks to donors. Post-donation glomerular…
2017 American Transplant Congress
TIE'ing Statins to Microvascular Stability and Endothelial Cell Immunogenicity.
C. Ghosh,¹ A. Mak,¹ M. McGourty,¹ S. Parikh,² X. Chen,² S. Goldberg,¹ J. Wedel,¹ D. Briscoe.¹
¹Transplant Research Program, Boston Children's Hospital, Boston, MA; ²Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, MA
Graft microvascular endothelial cells (EC) represent a critical interface between the recipient and the donor. Stable/quiescent EC support immunoregulation in part via the expression of…
2017 American Transplant Congress
Saftey & Long Term Outcomes of Tocilizumab (Anti-IL6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly-HLA Sensitized (HS) Patients (PTs).
J. Choi,¹ O. Aubert,² A. Vo,¹ A. Loupy,² M. Haas,³ S. Louie,¹ A. Kang,¹ A. Peng,¹ R. Najjar,¹ E. Huang,¹ M. Toyota,⁵ X. Zhang,⁴ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Transplant Group, University Paris Descartes, Paris, France; ³Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA; ⁴Department of HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ⁵Transplant Immunology Lab, Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: DSAs in HS pts lead to poor allograft survival & return to a dialysis. Treatment options for CABMR and TG are limited. IL-6 appears…
2017 American Transplant Congress
Generation of Natural Antibodies Post Transplant and Association with Kidney Allograft Loss.
S. See,¹ A. Loupy,² O. Aubert,² Y. Veras,¹ X. Lebreton,² B. Gao,³ C. Legendre,² D. Anglicheau,² E. Zorn.¹
¹Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY; ²Department of Kidney Transplantation, Hopital Necker, Université Paris, René Descartes and APHP, Paris, France; ³The First Hospital of Jilin University, Changchun, China
The development of donor specific antibodies (DSA) reacting to mismatched donor class I and class II HLA is a prominent risk factor for kidney graft…